SCHEMBL4891941

SCHEMBL4891941

COC(=O)CCc1ccc(OCc2ccccc2)c(CNC(=O)OC(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.47
CYP2C9 P11712 1/20 0.46
PTGER1 P34995 1/20 0.46
FFAR1 O14842 1/20 0.45
MTNR1A P48039 5/20 0.44
MTNR1B P49286 4/20 0.44
PPARD Q03181 2/20 0.44
APP P05067 1/20 0.44
PPARG P37231 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CCR5 P51681 1/20 0.43
LMNA P02545 1/20 0.42
OPRK1 P41145 1/20 0.42
PPARA Q07869 1/20 0.42
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6681179 0.82 CYP2C9 (0.47) CYP2C9PTGER1MTNR1AMTNR1BPPARD
SCHEMBL3418906 0.82 CCR5 (0.64) PTGER1MEN1KMT2ACCR5LMNA
SCHEMBL4896209 0.80 FFAR4 (0.58) FFAR4CYP2C9PTGER1FFAR1MTNR1A
SCHEMBL4893909 0.80 HDAC1 (0.43) PPARDAPPPPARAHDAC1
SCHEMBL4893421 0.79 FFAR4 (0.54) FFAR4CYP2C9PTGER1FFAR1MTNR1A
SCHEMBL4893142 0.79 PPARG (0.51) PPARDPPARGPPARA
SCHEMBL6330920 0.79 MRGPRX4 (0.47) CYP2C9PTGER1PPARDPPARGCCR5
SCHEMBL6781372 0.79 GLS (0.53)
SCHEMBL4895293 0.78 FFAR4 (0.52) FFAR4PTGER1FFAR1MTNR1AMTNR1B
SCHEMBL3415333 0.77 CYP2C9 (0.44) FFAR4CYP2C9PTGER1MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167310-A1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) GOSSETT LYNN STACY 2008-07-10 US disclosed
US-20080167310-A1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) GOSSETT LYNN STACY 2008-07-10 US disclosed
US-20080167310-A1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) GOSSETT LYNN STACY 2008-07-10 US disclosed
US-7282501-B2 Modulators of peroxisome proliferator activated receptors (PPAR) ELI LILLY AND COMPANY (US) 2007-10-16 US disclosed
US-7282501-B2 Modulators of peroxisome proliferator activated receptors (PPAR) ELI LILLY AND COMPANY (US) 2007-10-16 US disclosed
US-7282501-B2 Modulators of peroxisome proliferator activated receptors (PPAR) ELI LILLY AND COMPANY (US) 2007-10-16 US disclosed
EP-1401434-B1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) LILLY CO ELI (US) 2006-11-15 EP disclosed
US-20050075378-A1 Modulators of peroxisome proliferator activated receptors (ppar) ELI LILLY AND COMPANY 2005-04-07 US disclosed
EP-1401434-A1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) ELI LILLY AND COMPANY (US) 2004-03-31 EP disclosed
WO-2002100403-A1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) ELI LILLY AND COMPANY (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075378-A1 Modulators of peroxisome proliferator activated receptors (ppar) PPARG, PPARA, PPARD FFAR4 16/4885CYP2C9 922/4885PTGER1 206/4885
US-20080167310-A1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) PPARG, PPARA, PPARD FFAR4 16/4885CYP2C9 922/4885PTGER1 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.